Quick Facts

• Primary Use: Treatment of various mild to moderate bacterial infections.
• Respiratory Support: May be prescribed for community-acquired pneumonia and acute bacterial sinusitis.
• Skin and Tissue: Used to manage uncomplicated skin and soft tissue infections.
• Other Conditions: Relevant for specific sexually transmitted infections and middle ear infections.

---

Zepac (azithromycin) is a treatment option indicated for managing a range of mild to moderate bacterial infections. It may be used to address conditions in adult patients, including acute bacterial exacerbations of chronic bronchitis and acute bacterial sinusitis.

For respiratory tract concerns, Zepac is a consideration for community-acquired pneumonia in patients who are appropriate for oral therapy. The treatment is also relevant for pharyngitis and tonsillitis when a first-line therapy cannot be used. It is further employed for the management of uncomplicated skin and skin structure infections.

In the pediatric patient population, Zepac is utilized for acute otitis media (ear infection) and community-acquired pneumonia in children 6 months of age and older. It is also an alternative treatment for pharyngitis/tonsillitis in children over the age of two.

Zepac is used only to treat infections that are proven or strongly suspected to be caused by bacteria, as part of an effort to minimize the development of drug-resistant bacteria.

Official Eligibility and Restrictions for Zepac

The eligibility for Zepac (azithromycin) is determined by regulatory authorization, defining approved age groups and establishing absolute non-use criteria.

Contraindicated Populations (Must Not Use):

• Patients with a known hypersensitivity to azithromycin, erythromycin, or any macrolide or ketolide antibiotic.
• Patients with a history of cholestatic jaundice or hepatic dysfunction associated with previous azithromycin use.

Age-Related Eligibility:

Age Group	Eligibility Status (Regulatory)
Infants	Safety and effectiveness have not been established for infants under 6 months of age for most indications.
Children	Approved for specific uses in children 6 months of age and older.
Older Adults	Used with caution due to increased susceptibility to torsades de pointes cardiac arrhythmias.

Conditional Use and Specific Restrictions:

Use of Zepac requires caution or is restricted in the presence of certain conditions, as documented in official labeling:

• Cardiovascular Risk: Caution is advised for patients with known QT interval prolongation or other proarrhythmic conditions.
• Organ Impairment: Caution is required for patients with significant hepatic disease or severe renal impairment (GFR <10 mL/min).
• Myasthenia Gravis: Use may exacerbate muscle weakness in individuals with this condition.
• Pregnancy/Lactation: Use during pregnancy is conditional—only if clearly needed. Azithromycin is present in human milk.

Interactions with other medicines and products

The regulatory profile for Zepac (Ketorolac tromethamine) identifies several combinations that are formally restricted due to documented interaction patterns.

Formal Contraindicated Combinations

Co-administration is officially contraindicated with Probenecid, as this drug significantly decreases Zepac's clearance, leading to elevated plasma levels. The use of Zepac is also contraindicated with Aspirin or any other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) due to the cumulative and heightened risk of serious NSAID-related complications. Furthermore, due to the inhibition of platelet function, combination with Anticoagulants (such as Warfarin) or Lithium salts is strictly prohibited in official labeling.

---

Pharmacodynamic and Exposure-Modifying Interactions

Zepac demonstrates clinically significant exposure-modifying interactions by decreasing the renal clearance of substances like Methotrexate, thereby increasing its plasma toxicity. A pharmacodynamic interaction exists with Diuretics (e.g., Furosemide) and antihypertensive agents (e.g., ACE Inhibitors), as Zepac's action can diminish their expected natriuretic or blood-pressure-lowering effects. The official documents also note that Alcohol consumption raises the synergistic risk of gastrointestinal bleeding and ulceration. For all formulations, the total combined duration of use must not exceed five days in adults due to safety restrictions associated with prolonged therapy. Elderly patients are noted as a population where slower clearance may increase sensitivity to documented interaction effects.

How Zepac Works: Mechanism of Action

Targeted Receptor and Enzyme Modulation

Zepac acts by engaging defined biological targets within specific receptor or enzyme systems. This modulation is defined by its selective interaction with key molecular targets, where the compound initiates or suppresses specific signaling events at the molecular level.

---

Modifying Signal Transduction Pathways

Once the primary target is engaged, Zepac operates within well-characterized molecular cascades to alter signaling dynamics. This mechanism alters signal transduction to reduce heightened pathway activity and influence the rate of signaling events, particularly in contexts involving high pathway activation.

---

Influence on Physiological Processes

The resulting action influences key regulatory systems, leading to a modification of physiological processes. By altering pathway activity, the compound modifies the activity of key mediators within the affected pathways, which defines the resulting physiological changes.

Zepac (Ketorolac tromethamine) is administered according to a strict, sequential protocol for short-term systemic therapy. The medicine is indicated for systemic use via Intravenous (IV) or Intramuscular (IM) injection, as well as Oral tablets, and for local application as a Topical (Ophthalmic) Solution.

The administration of Zepac is structured by a core principle of sequential use. Systemic treatment must be initiated with an injection, and the use of oral tablets is not intended as a starting dose, functioning only as a short-term continuation of therapy. Crucially, the maximum total combined duration of Zepac administered systemically (IV/IM and Oral) must not exceed five days.

Official Dosing and Administration Rules

• Dosing Frequency: Systemic doses are maintained on a fixed-interval schedule, such as 30 mg every 6 hours for parenteral use or 10 mg every 4–6 hours for oral maintenance. The maximum total dose is limited (e.g., 120 mg/day parenteral; 40 mg/day oral).
• Preparation: The IV bolus must be administered slowly, requiring a duration of no less than 15 seconds for injection.
• Population Adjustments: Mandatory dose adjustments are required for certain groups. Patients 65 years of age and older or those with lower body weight (<50 kg) must receive a reduced maximum daily dose (e.g., restricted to 60 mg/day for parenteral administration).

This precise procedural framework ensures the medicine is used strictly within established administration limits.

Research evidence / Overview of Studies for Zepac (Ketorolac Tromethamine)

---

Evidence Supporting Short-Term Pain Relief (Systemic Use)

The clinical research involving Zepac tablets and injections was primarily conducted in settings associated with conditions that involve acute or disruptive episodes, such as pain following surgical procedures. Research primarily consists of short-term Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. These studies explored how symptoms change over time and focused on patient-reported outcomes describing perceived discomfort. The main populations observed were non-elderly adults in post-operative or emergency room settings.

Studies monitored how patients’ reported pain intensity evolved during defined time intervals, usually over a few hours up to 48 hours. Findings describe patterns observed in the studies related to differences in patient-reported discomfort scores compared to a placebo or other study treatments. Research also describes the monitoring of opioid medication requested by observed patients during the study period. This evidence contributes to the broader understanding of symptom patterns in conditions characterized by heightened symptom activity.

Comparative Research and Opioid-Sparing Studies

Research examined Zepac alongside traditional opioid-based medications and non-active placebo controls. Systematic reviews and meta-analyses, which combine data from multiple RCTs, were applied in studies examining patient-reported experiences related to physical discomfort. Findings indicate that when Zepac was included in the plan, studies observed data related to the measurement of total opioid doses in the study groups.

Some research highlights a pattern where studies observed that measurements of patient-reported discomfort did not increase consistently even when higher amounts of the medicine were studied. This research provides insight into short-term changes in medication usage.

Research for Topical Ophthalmic Use

Zepac ophthalmic solution was studied for conditions involving acute or disruptive episodes associated with eye procedures, such as cataract surgery or corneal refractive surgery. This evidence is derived from multi-center, double-masked, vehicle-controlled clinical trials. These studies primarily monitored outcomes linked to inflammatory or irritative states and patient-reported outcomes describing perceived discomfort in the eye.

Studies explored how post-operative inflammation was monitored by clinical measures, as well as outcomes related to specific physical discomfort, such as pain, burning, and light sensitivity (photophobia). Research indicates that in the observed populations, differences were measured in the reported levels of inflammation and the patient's perceived discomfort compared to those receiving the inactive vehicle solution. The typical follow-up durations were short-to-intermediate term, usually not exceeding two weeks post-procedure.

Long-Term Data and Evidence Duration

The overall evidence landscape for Zepac’s systemic use is characterized by strict limits on follow-up durations. For injections and tablets, the research exploring short-term symptom changes was limited to a maximum of five days in the critical regulatory trials. There is limited information for long-term outcomes, and long-term effects are not fully established beyond this short period.

Common questions about Zepac (FAQ)

Q: What is the difference between Zepac and Ibuprofen?

A: Zepac (Ketorolac tromethamine) is a Nonsteroidal Anti-inflammatory Drug (NSAID) used for pain management. Official regulatory documents specify that it is approved only for the short-term (up to five days) management of moderately severe acute pain. Ibuprofen is generally approved for mild to moderate pain relief and inflammation. Furthermore, regulatory labeling for Zepac contains a strong warning (Boxed Warning) for the increased risk of serious gastrointestinal and cardiovascular events, which strictly limits its use compared to other NSAIDs.

Q: What is the right temperature to store the oral tablets?

A: The official labeling states that the oral tablets should be stored at controlled room temperature. Regulatory documents state that the controlled room temperature is generally between 20 C to 25 C (68 F to 77 F), as indicated in the official product information.

Q: How does Zepac work to reduce pain?

A: Zepac is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). According to the official product information, it works by blocking the production of prostaglandins. These are chemical messengers in the body that transmit pain signals and trigger the inflammatory response, which is the action that helps the medication provide pain relief and anti-inflammatory effects.

Q: What are the most common uses for the ophthalmic solution?

A: Regulatory documents indicate that the ophthalmic solution is used for two main purposes. It is officially indicated for the temporary relief of itching in the eye caused by seasonal allergic conjunctivitis. It is also prescribed for the treatment of inflammation that occurs following cataract surgery.

Q: When do I have to throw away the oral liquid suspension?

A: The official product information states that the mixed oral liquid suspension has a strict 10-day stability limit. Therefore, it must be discarded after the full prescribed dosing is complete or after the 10-day period has passed, whichever comes first, to adhere to official product stability guidelines.

Q: Which parts of the body does Ketorolac affect to cause side effects?

A: Adverse reactions are formally cataloged across several different physiological systems. Official documentation reports that adverse reactions are often linked to the following body systems: Gastrointestinal (stomach/intestines), Nervous (brain/nerves), Cardiovascular (heart), and Hepatobiliary (liver) systems.

Q: What are the symptoms of a Zepac overdose?

A: Official information regarding acute NSAID overdose notes that symptoms may include nausea, vomiting, pain in the upper abdomen, and gastrointestinal bleeding. Additional symptoms noted in regulatory reports have included drowsiness and a lack of energy.

How to Store and Dispose of Zepac

Storage Conditions: Azithromycin tablets and the dry powder for oral suspension must be stored at controlled room temperature, typically 15 C to 30 C (59 F to 86 F). The reconstituted liquid suspension may be stored at room temperature or refrigerated, but must not be frozen. All forms must be kept in the original, tightly closed container and out of the sight and reach of children.

Stability and Disposal: The mixed oral suspension has a strict 10-day stability limit and must be discarded after this period, regardless of whether it is refrigerated. Any unused portion of the suspension must be discarded after the full prescribed dosing is completed. Azithromycin is not on the FDA's flush list and should be disposed of via drug take-back programs or household trash following local regulatory guidance.